Monopar Therapeutics MNPR Increase (Decrease) in Other Current Assets
Increase (Decrease) in Other Current Assets at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherCurrentAssets.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's increase (decrease) in other current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's increase (decrease) in other current assets?
- Monopar Therapeutics (MNPR) reported increase (decrease) in other current assets of $187.04K in Q1 2026.
- How has Monopar Therapeutics's increase (decrease) in other current assets changed year-over-year?
- Monopar Therapeutics's increase (decrease) in other current assets decreased by 62.7% year-over-year, from $502.03K to $187.04K.
- What is the long-term trend for Monopar Therapeutics's increase (decrease) in other current assets?
- Over 3 years (2021 to 2025), Monopar Therapeutics's increase (decrease) in other current assets has grown at a -43.7% compound annual growth rate (CAGR), from -$86.2K to -$15.4K.